Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of ERY974 in advanced or metastatic hepatocellular carcinoma
jRCT2031200382Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of ERY974 in hepatocellular carcinoma (HCC), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Safety. Started Jun 2021; status: completed.
02
Drugs
ERY974
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2031200382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200382.